GMP Recombinant Human IFNA1 protein
Recombinant Human IFNA1 was expressed in HEK293.
Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4, containing 4 % mannitol and 1 % HSA.
Fully biologically active when compared to standard. The specific activity determined by an anti-viral assay is no less than 1.0 × 10^8 IU/mg.
Approximately 19.5 kDa, a single non-glycosylated polypeptide chain containing 167 amino acids.
MCDLPETHSL DNRRTLMLLA QMSRISPSSC LMDRHDFGFP QEEFDGNQFQ KAPAISVLHE LIQQIFNLFT TKDSSAAWDE DLLDKFCTEL YQQLNDLEAC VMQEERVGET PLMNVDSILA VKKYFRRITL YLTEKKYSPC AWEVVRAEIM RSLSLSTNLQ ERLRRKE
Less than 1 EU/µg of rHuIFN-α1b as determined by LAL method.
> 96 % by SDS-PAGE and HPLC analyses.
This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.
This lyophilized preparation is stable at 2-8 centigrade, but should be kept at -20 centigrade for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 centigrade. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 centigrade to -70 centigrade. Avoid repeated freeze/thaw cycles.
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 centigrade. Further dilutions should be made in appropriate buffered solutions.